URINE CYTOLOGY AND AXILLARY TESTING FOR INTERPRETATION AND FOLLOW-UP OF URINARY TUMORS. [PDF]
Acta Clin Croat, 2022 Kalogeraki AM +2 more
europepmc +1 more source
The FASEB Journal, Volume 40, Issue 15, 15 August 2026.Subjects were divided into HC, NHIC, and HIC groups. Clinical Characteristics, urinary ultrasound parameters, and urinary biomarkers were collected for ML screening of predictive signatures. DEGs are identified from GEO transcriptomic data; scRNA‐seq delineates cell clusters, pseudotime trajectories and intercellular communication.
Cheng Luo +5 more
wiley +1 more source
Diagnostic Significance of Cytokeratin 20 and p53 as Adjunct Immunocytological Markers in Urine Cytology to Detect Urothelial Carcinomas: A Systematic Review Study. [PDF]
Iran J Pathol, 2023 Angel E.
europepmc +1 more source
Epithelioid cell granulomas in urine cytology smears: A diagnostic approach. [PDF]
Cytojournal, 2022 Gupta D, Kaushal M, Jain S.
europepmc +1 more source
Investigating gender disparities in urological care for non‐muscle invasive bladder cancer (NMIBC)
BJUI Compass, Volume 7, Issue 8, August 2026.Abstract Objective This study aims to explore possible gender disparities in urological diagnostic and therapeutic care for NMIBC, particularly in the use of enhanced endoscopic imaging techniques. Materials and Methods An international survey in seven languages was distributed to all members of the Société Internationale d'Urologie (SIU).
Aleyna Aydin +10 more
wiley +1 more source
Examining longitudinal markers of bladder cancer recurrence through a semiautonomous machine learning system for quantifying specimen atypia from urine cytology. [PDF]
Cancer Cytopathol, 2023 Levy JJ +12 more
europepmc +1 more source
What Is Your Diagnosis? Lymph Node Aspirate From a Dog
Veterinary Clinical Pathology, EarlyView.
William Benedict +3 more
wiley +1 more source
Diagnostic performance of nuclear matrix protein 22 and urine cytology for bladder cancer: A meta-analysis. [PDF]
Diagn Cytopathol, 2022 Wang J +5 more
europepmc +1 more source
A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2‐Positive Metastatic Breast Cancer
Cancer Medicine, Volume 15, Issue 8, August 2026.ABSTRACT Ibrutinib has demonstrated inhibition of ErbB/HER tyrosine kinases in preclinical models. This Phase I/II study investigated the safety, efficacy, and immunomodulatory effects of ibrutinib in combination with trastuzumab in patients with HER2‐positive metastatic breast cancer (MBC) whose disease had progressed on ado‐trastuzumab emtansine ...
Joyce O'Shaughnessy +10 more
wiley +1 more source
Clinical Case Reports, Volume 14, Issue 8, August 2026.ABSTRACT Primary large‐cell neuroendocrine carcinoma of the bladder is highly invasive and has a poor prognosis. However, early curative treatment may lead to a good prognosis.
Shun Aoki +12 more
wiley +1 more source